On December 29, 2025, Inovio Pharmaceuticals announced that the FDA has accepted its Biologic License Application for INO-3107, aimed at treating recurrent respiratory papillomatosis in adults, with a review goal date set for October 30, 2026. The FDA noted potential review issues regarding the eligibility for accelerated approval, prompting the company to seek a meeting to discuss next steps.